<DOC>
	<DOCNO>NCT02534311</DOCNO>
	<brief_summary>The purpose clinical trial prospectively evaluate RA activity use assessment change DAS28 local condition Slovakia participant treat subcutaneously administer tocilizumab pursuant recommendation Ministry Health Slovak Republic order well assess disease activity impairment joint function .</brief_summary>
	<brief_title>A Phase IV Study Evaluate Effect Subcutaneous ( SC ) Tocilizumab Administered Participants With Rheumatoid Arthritis ( RA ) Assessed Using Disease Activity Score ( DAS28 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Participants age great equal ( &gt; = ) 18 year Participants moderate severe active RA ( DAS28 &gt; =3.2 ) respond sufficiently tolerate previous treatment one several diseasemodifying antirheumatic drug ( DMARDs ) , irrespective whether biological synthetic nature Participants eligible treatment subcutaneously administer tocilizumab , decide doctor accordance summary product characteristic ( SPC ) standard therapeutic procedure , previously treat tocilizumab receive biological treatment RA past either Assignment participant observation use treatment describe clearly separated physician 's decision prescribe treatment patient . Pulmonologist 's consent chest Xray quantiferon test commencement biological treatment Hepatitis B surface antigen ( HBsAg , ) hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) positivity History severe allergic anaphylactic response human humanize murine monoclonal antibody History intestinal ulceration diverticulitis Active hepatopathy threefold increase alanine transaminase ( ALT ) aspartate transaminase ( AST ) Thrombocytes &lt; 100,000 per cubic milliliter ( /mm^3 ) , less ( &lt; ) 3,000 mm^3 , absolute neutrophil count &lt; 2,000 mm^3 Women childbearing age ( without medically confirm sterility , e.g . follow hysterectomy , ovariectomy , menopause last 2 year ) accept use suitable form contraception ( e.g . barrier method contraception participant partner , contraceptive pill patch , hormonal implant , spermicidal agent combination barrier method contraception , intrauterine device )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>